Top 20 Venture Capital Firms

Life Sciences Tools & DiagnosticsMedical DevicesBiotechnology / Pharmaceuticals

Source: Genetic Engineering and Biotechnology News (12/18/12)

"Venture capital firms, in exchange for equity in the companies in which they’re investing, can help provide funds for companies they think have high potential. So, which VC firms have helped pump up the most biotech and biopharma companies?"

In order to start up a company, one must have capital, and for some companies, a venture capital firm may be the best source for it. Venture capital firms, in exchange for equity in the companies in which they’re investing, can help provide funds for companies they think have high potential. So, which VC firms have helped pump up the most biotech and biopharma companies? Below is a list of top venture capital firms and broader financial firms that invest venture capital or other equity in early- to late-stage biotechnology and pharmaceutical companies, ranked by total capital under management or, for some firms, total active "committed" capital from funds in use.

Genetic Engineering and Biotechnology News

Biotech Discovers Revolutionary Immunotherapy in Houston
Source: Jason Kolbert (04/24/2025)

Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note.

Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs
Source: Streetwise Reports (04/24/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company.

Analyst Reveals Undervalued Pharmaceutical Gem in Canada
Source: Dr. Douglas Loe (04/14/2025)

In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential.

Four-Year Data on New Drug for Early AD Positive
Source: Dr. Ram Selvaraju (04/09/2025)

Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report.

Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Source: Jason Kolbert (04/09/2025)

These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report.